Comparing methods for targeting radiation therapy in spinal tumors

Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors

This study is testing two different ways to target radiation therapy for spinal tumors to see which method works better and has fewer side effects for patients.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Ages: 18 Years to 90 Years
• Sex: All
• Sponsor: Peking University Third Hospital (other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06587022 on ClinicalTrials.gov

What this trial studies

This study aims to compare the efficacy and side effects of two different methods for delineating target volumes in stereotactic radiotherapy for metastatic spinal tumors. Approximately 500 patients will be enrolled and divided into two groups based on the target delineation method used: one group will focus solely on the local tumor, while the other will include both the local tumor and the adjacent vertebral area. The study is observational and will assess outcomes based on imaging data and patient follow-up after treatment.

Who should consider this trial

Good fit: Ideal candidates include patients with spinal metastases or primary tumors who are receiving stereotactic radiotherapy and have sufficient pre-treatment imaging data.

Not a fit: Patients with an expected survival of less than 3 months or those with extensive spinal metastasis without local therapeutic value may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment outcomes and reduced side effects for patients undergoing stereotactic radiotherapy for spinal tumors.

How similar studies have performed: While this study focuses on a specific comparison of target delineation methods, similar approaches in radiation therapy have shown promise in improving treatment efficacy and safety.

Eligibility criteria

Inclusion Criteria:

* Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy;
* Patients with sufficent pre-treatment imaging data
* Patients who can cooperate with imaging review and follow-up after radiotherapy.

Exclusion Criteria:

* Patients with an expected survival of less than 3 months;
* Patients with second-course radiotherapy;
* Patients with physical conditions that cannot tolerate stereotactic radiotherapy;
* Patients with extensive spinal metastasis and no local therapeutic value

Where this trial is running

Beijing, Beijing Municipality

• Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist. — Beijing, Beijing Municipality, China (RECRUITING)

Study contacts

• Study coordinator: Hongqing Zhuang, Doctor

Conditions: Spinal Tumor